Kexing Biopharma Receives Approval for GB20 Clinical Trials

Kexing Biopharma, a leading biopharmaceutical company, has taken a significant step forward in its research and development efforts by receiving approval from China’s National Medical Products Administration (NMPA) to initiate clinical trials for its investigational anti-TL1A monoclonal antibody, GB20. This approval is a critical milestone in the company’s ongoing efforts to develop innovative treatments for inflammatory bowel disease (IBD).

GB20, developed using the company’s proprietary KX-BODY antibody technology platform, targets TL1A, a member of the tumor necrosis factor (TNF) superfamily that plays a central role in IBD pathogenesis. The drug is designed to offer a dual mechanism of action, suppressing inflammation and delaying fibrosis, potentially providing a more comprehensive approach to managing the disease.

According to the press release, preclinical findings for GB20, published in Frontiers in Immunology, have shown a differentiated profile. The antibody demonstrated improvements in disease activity scores, colon morphology, and histopathologic signs of inflammatory injury. Additionally, GB20 exhibited a long half-life in pharmacokinetic studies, which could support longer dosing intervals and reduce injection frequency, thereby improving patient adherence.

Kexing Biopharma is not the only player in its pipeline. The company is also advancing several other differentiated programs, including GB19, an anti-BDCA2 monoclonal antibody for lupus, which has received clearance from both the NMPA and the U.S. Food and Drug Administration (FDA). Other programs include GB24, a bispecific antibody for IBD; GB12, a bispecific antibody targeting IL-4R and IL-31; and GB26, a bispecific antibody for systemic lupus erythematosus.

In recent years, Kexing Biopharma has focused on oncology and autoimmune diseases, accelerating the development of more than 10 innovative drug programs. The company is forming a staged pipeline that spans discovery, clinical development, and regulatory filing, positioning itself as a leader in the biopharmaceutical industry.

Kexing Biopharma has also expanded its global presence, establishing a sales presence in approximately 70 countries and regions. With established capabilities in overseas registration, market access, and commercialization, the company aims to become an innovation-driven global biopharmaceutical company, bringing more high-quality products to patients worldwide.